Cakile maritima Scop. extracts inhibit the growth of some bacterial triggers of autoimmune diseases: GC-MS analysis of an inhibitory extract

Omer, Elsayed A.; Elshamy, Abdelsamed I.; Gendy, Abdel Nasser El; Cai, Xin; Sirdaarta, Joseph; White, Alan; Cock, Ian Edwin

doi:10.5530/pj.2016.4.9

Cited by 15 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three esters (Heptadecanoic acid, methyl ester; 9-octadecenoic acid (Z)-, methyl ester; Oxalic acid, 6-ethyloct-3-YL heptyl ester) were also found in cyanobacterial extract. Heptadecanoic acid, methyl ester from Mentha spicata 31 , 9-octadecenoic acid (Z)-, methyl ester from Thesium humile Vahl 41 and Oxalic acid, 6-ethyloct-3-YL heptyl ester from Cakile maritima 42 were also reported for their good reducing potential. Apart from the esters, two carboxylic acids i.e.…”

Section: Discussionmentioning

confidence: 99%

Biomedical potential of Anabaena variabilis NCCU-441 based Selenium nanoparticles and their comparison with commercial nanoparticles

Afzal

Yasin

Naaz

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Selenium nanoparticles (SeNPs) are gaining importance in the field of medicines due to their high surface area and unique properties than their other forms of selenium. In this study, biogenic selenium nanoparticles (B-SeNPs) were synthesized using cyanobacteria and their bioactivities (antioxidant, antimicrobial, anticancer and biocompatibility) were determined for comparison with commercially available chemically synthesized selenium nanoparticles (C-SeNPs). Color change of reaction mixture from sky blue to orange-red indicated the synthesis of biogenic SeNPs (B-SeNPs). UV–Vis spectra of the reaction mixture exhibited peak at 266 nm. During optimization, 30 °C of temperature, 24 h of time and 1:2 concentration ratio of sodium selenite and cell extract represented the best condition for SeNPs synthesis. Various functional groups and biochemical compounds present in the aqueous extract of Anabaena variabilis NCCU-441, which may have possibly influenced the reduction process of SeNPs were identified by FT-IR spectrum and GC–MS. The synthesized cyanobacterial SeNPs were orange red in color, spherical in shape, 10.8 nm in size and amorphous in nature. The B-SeNPs showed better anti-oxidant (DPPH, FRAP, SOR and ABTS assays), anti-microbial (antibacterial and antifungal) and anti-cancer activitities along with its biocompatibility in comparison to C-SeNPs suggesting higher probability of their biomedical application.

show abstract

Section: Discussionmentioning

confidence: 99%

Biomedical potential of Anabaena variabilis NCCU-441 based Selenium nanoparticles and their comparison with commercial nanoparticles

Afzal

Yasin

Naaz

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…CAM) research has accelerated in the past years, which may have a potential in the treatment of multiple sclerosis and several other autoimmune diseases. For instance, Cakile maritima extract, 57 Cammiphora molmol oleo-resin, 58 and Duboisia leichhardtii 59 are found to suppress the activity of a number of bacteria that are suggested to trigger an immune response; thus, may have a potential in the management of MS. Fumaria indica is another interesting natural product, which is found to act centrally and exert an anxiolytic effect; in addition to, suppressing cytokines count in the brain. 60 Nevertheless, these natural extracts and resins are still in the experimental and preclinical stages.…”

Section: Managementmentioning

confidence: 99%

Available Pharmacological Options and Symptomatic Treatments of Multiple Sclerosis

Bazzari¹

2018

SRP

View full text Add to dashboard Cite

Multiple sclerosis is an autoimmune disease that targets the central nervous system and exposes the patients to a higher risk of various disabilities that impair their normal daily life activities. Different approaches take a part in the management of multiple sclerosis, in which pharmacological drug therapy is the corner stone and the central player in the treatment of multiple sclerosis. The pharmacological therapy can be categorized into; disease modifying therapies, symptomatic treatments, and relapse management. The discussed disease modifying therapies include; alemtuzumab, dimethyl fumarate, fingolimod, glatiramer acetate, natalizumab, teriflunomide and beta Interferon-1B, that have been found to share a characteristic feature of altering the immune system baseline functions in order to limit multiple sclerosis complications and deaccelerate its progression. The frequently occurring symptoms of multiple sclerosis are; depression, fatigue, general pain, spasticity, muscle spasm and other symptoms, that need to be carefully managed. Patients with multiple sclerosis face "on and off" episodes of aggravated symptoms known as a relapse that may last for days, weeks or even months. The National Institute for Health and Care Excellence guidelines have recommended the use of high corticosteroid doses as the gold-standard practice in managing a relapse episode. This review article will provide an overview of the different pharmacological therapies and their major role in the management of multiple sclerosis; via exploring the most recent published scientific evidence. In the end, a general discussion is added, focusing on the role of pharmacists and other medical experts in the clinical management of multiple sclerosis and patient support.

show abstract

“…Indeed, the ability of plant extracts to block the growth of pathogenic bacteria has become a focus of substantial recent study. [1][2][3][4][5] Much of the research into traditional medicinal plant use has focused on Asian, [6][7][8] African, [9][10][11] Middle Eastern [12][13][14] and South American 15 plants. However, despite the potential of plants to provide us with useful pharmaceutical agents, the field is still relatively poorly studied.…”

Section: Introductionmentioning

confidence: 99%

An Examination of the Antioxidant Capacity, Antibacterial Activity and Toxicity of Commercial Kale and Spirulina Powders

Blanc¹,

Cock²

2021

Self Cite

View full text Add to dashboard Cite

Introduction:The development of antibiotic resistant bacteria has resulted in treatment failure for the current antibiotic regimen against many bacteria. A corresponding decrease in the development of new antibiotic therapies has highlighted the urgent need for the discovery of new antibiotics. An examination of 'superfoods' is an attractive option due to the high antioxidant capacities and beneficial secondary compounds reported in many 'superfoods'. This study was undertaken to test kale and spirulina extracts for the ability to inhibit the growth of a panel of bacterial pathogens of human importance. Methods: Commercially sourced kale and spirulina powders were extracted and tested for antimicrobial activity using modified disc diffusion and liquid dilution MIC methods. Toxicity was evaluated using an Artemia franciscana nauplii bioassay. Results: The methanolic and aqueous extracts of kale and spirulina displayed noteworthy growth inhibitory activity against P. mirabilis. The aqueous spirulina extract was a particularly good inhibitor of P. mirabilis, with MIC values as low as 220μg/mL. In contrast, all extracts were ineffective or of low inhibitory activity against all other bacteria tested. All extracts were non-toxic in the Artemia nauplii bioassay, confirming their suitability as natural antibacterial therapies. Conclusion: These studies indicate that aqueous kale and spirulina extracts are promising inhibitors of P. mirabilis growth and may be useful in the prevention and treatment of rheumatoid arthritis, as well as other diseases caused by that bacterium.

show abstract

Cakile maritima Scop. extracts inhibit the growth of some bacterial triggers of autoimmune diseases: GC-MS analysis of an inhibitory extract

Cited by 15 publications

References 23 publications

Biomedical potential of Anabaena variabilis NCCU-441 based Selenium nanoparticles and their comparison with commercial nanoparticles

Biomedical potential of Anabaena variabilis NCCU-441 based Selenium nanoparticles and their comparison with commercial nanoparticles

Available Pharmacological Options and Symptomatic Treatments of Multiple Sclerosis

An Examination of the Antioxidant Capacity, Antibacterial Activity and Toxicity of Commercial Kale and Spirulina Powders

Contact Info

Product

Resources

About